Bank Julius Baer & Co
VNDA icon

Bank Julius Baer & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

Bank Julius Baer & Co’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400
Closed -$6K – 808
2021
Q4 		$6K Buy
+400
New +$6.97K ﹤0.01% 805

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank Julius Baer & Co's VNDA Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 400 shares — an estimated $6K sold.

Bank Julius Baer & Co first reported a position in VNDA in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 400 Vanda Pharmaceuticals shares in Q1 2022, an estimated $6K.
  • Bank Julius Baer & Co first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's Vanda Pharmaceuticals position peaked at $6K in Q4 2021.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.